Explore current and emerging treatments for multiple myeloma in this informative community lecture featuring UCLA hematologist and oncologist Dr. Sarah M. Larson. Moderated by Leila Evangelista from the Leukemia & Lymphoma Society, the talk covers a wide range of topics including the immune system, plasma cells, M protein, disease spectrum, and CRAB criteria. Delve into various treatment approaches, response rates, and the concept of minimal residual disease. Learn about cutting-edge therapies such as Venetoclax, immunotherapy targeting BCMA and BLEN, and CAR T-cell treatments, including their side effects and ongoing clinical trials. Gain insights into the latest research, including the Storm, Karma 3, and Karma 4 trials, and discover efforts to design more effective CAR T-cells. The lecture concludes with information on clinical trials and the Climb to Cure initiative, followed by a Q&A session.
Novel Therapies for Multiple Myeloma - Closer to a Cure Community Lecture Series
University of California, Los Angeles via YouTube
Overview
Syllabus
Introduction
Objectives
The Immune System
The Plasma Cell
The M Protein
The Spectrum of Disease
The Crab Criteria
Treatment
Response
remission
response rates
complete response
Minimal residual disease
Storm Trial
Venetoclax
Immunotherapy
Targets
BCMA
BLEN Rep
CAR T Cells
CAR T Cells Side Effects
Lymphodepletion
Iacel
Karma 3 Trial
Karma 4 Trial
Clinical Trial Summary
Can We Design a Better CarT Cell
Clinical Trials
Climb to Cure
Thank you
Questions
Taught by
UCLA Health
